RecruitingPhase 2NCT06686043

HPV Vaccine, Imiquimod, and Metformin Combination Trial

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers


Sponsor

Baylor College of Medicine

Enrollment

85 participants

Start Date

Aug 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are: Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone. Participants will: Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation. Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit. Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether combining an HPV vaccine, a topical immune-stimulating cream (imiquimod), and a diabetes drug (metformin) with standard chemoradiation therapy can improve outcomes for women with advanced cervical, vaginal, or vulvar cancer. **You may be eligible if...** - You have been diagnosed with locally advanced or metastatic cervical, vaginal, or vulvar cancer - You are 18 years or older - You are eligible for chemoradiation treatment - Your tumor is accessible for injection - You are newly diagnosed with this cancer - Your organ function (blood counts, kidney, liver) is within required levels **You may NOT be eligible if...** - You are receiving another experimental treatment - You have untreated brain metastases - You have an uncontrolled infection or serious psychiatric illness - You are pregnant or breastfeeding - You have a known allergy to any of the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHPV vaccine, Imiquimod, and metformin combination therapy

Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.


Locations(2)

Baylor St. Luke's Medical Center- Dan L. Duncan Comprehensive Cancer Center

Houston, Texas, United States

Harris Health Smith Clinic

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06686043


Related Trials